We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > LY-CoV016

News List

Lilly Provides Update on SARS-CoV-2 Neutralizing Antibody Programs americanpharmaceuticalreview
October 14, 2020
Eli Lilly and Company announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild-to-moderate COVID-19 – and plans to make these therapies ...
Eli Lilly seeks EUA for monotherapy against Covid-19 pharmaceutical-technology
October 10, 2020
Eli Lilly has submitted an application to the US Food and Drug Administration (FDA) seeking emergency use authorisation (EUA) for LY-CoV555 monotherapy for treating higher-risk patients with mild-to-moderate Covid-19.